Tokyo-based clinical-stage biotechnology company founded in April 2022 to develop treatments for dementia and other central nervous system disorders from Tohoku University research. Its lead candidate NTX-083 is an orally administered small molecule being developed for Alzheimer’s disease with a new mechanism of action. The company conducts clinical development, builds backup compounds and explores additional brain-disease targets. By June 2026 it reported completing single- and multiple-dose Phase 1 studies in healthy adults and planned a US Phase 1b study in Alzheimer’s patients; cognitive benefits and disease modification remain development goals.
